Shandong Xinhua Pharmaceutical Company Limited (HKG:0719)

HKG:0719 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020
Operating Revenue	8,279	8,324	7,956	7,295	6,360	5,949
Other Revenue	142.44	142.44	144.78	207.82	200.54	56.85
Revenue	8,421	8,466	8,101	7,503	6,560	6,006
Revenue Growth (YoY)	6.12%	4.51%	7.97%	14.37%	9.23%	7.13%
Cost of Revenue	6,660	6,481	5,779	5,515	4,824	4,244
Gross Profit	1,762	1,985	2,321	1,988	1,736	1,762
Selling, General & Admin	841.11	1,017	1,287	1,106	929.12	943.96
Research & Development	381.07	413.18	419.24	345.66	341.37	298.35
Other Operating Expenses	45.78	35.88	92.18	65.31	59.27	60.28
Operating Expenses	1,276	1,475	1,809	1,522	1,332	1,303
Operating Income	485.35	510.63	512.15	465.87	403.67	458.77
Interest Expense	-41.47	-39.74	-41.15	-49.71	-53.1	-59.76
Interest & Investment Income	20.49	20.96	21.88	18.83	16.79	11.58
Currency Exchange Gain (Loss)	19.09	19.09	15.42	10.53	-4.18	-24.78
Other Non Operating Income (Expenses)	-0.98	-3.41	-2.72	-3.38	-2.45	-4.46
EBT Excluding Unusual Items	480.54	507.53	505.59	442.15	360.72	381.35
Gain (Loss) on Sale of Assets	2.34	1.42	8.73	5.54	2.07	2.49
Asset Writedown	-5.12	-5.12	-10.29	-2.61	-1.88	-4.43
Other Unusual Items	29.82	29.82	28.65	26.7	60.32	32.23
Pretax Income	507.57	533.65	532.69	471.77	421.23	411.64
Income Tax Expense	50.48	46.94	26.58	45.66	59.16	64.52
Earnings From Continuing Operations	457.09	486.71	506.11	426.11	362.07	347.11
Minority Interest in Earnings	-16.85	-16.69	-9.59	-15.05	-13.53	-22.25
Net Income	440.24	470.02	496.51	411.06	348.55	324.86
Net Income to Common	440.24	470.02	496.51	411.06	348.55	324.86
Net Income Growth	-9.56%	-5.33%	20.79%	17.94%	7.29%	8.30%
Shares Outstanding (Basic)	700	682	674	661	627	622
Shares Outstanding (Diluted)	706	688	692	671	627	627
Shares Change (YoY)	2.55%	-0.54%	3.20%	6.93%	-0.02%	0.86%
EPS (Basic)	0.63	0.69	0.74	0.62	0.56	0.52
EPS (Diluted)	0.62	0.68	0.72	0.61	0.56	0.52
EPS Growth	-12.52%	-5.56%	18.03%	9.75%	6.89%	8.33%
Free Cash Flow	128.98	155.19	-59.85	513.48	9.89	140
Free Cash Flow Per Share	0.18	0.23	-0.09	0.77	0.02	0.22
Dividend Per Share	0.275	0.275	0.250	0.200	0.150	0.150
Dividend Growth	10.00%	10.00%	25.00%	33.33%	-	25.00%
Gross Margin	20.92%	23.45%	28.66%	26.50%	26.46%	29.33%
Operating Margin	5.76%	6.03%	6.32%	6.21%	6.15%	7.64%
Profit Margin	5.23%	5.55%	6.13%	5.48%	5.31%	5.41%
Free Cash Flow Margin	1.53%	1.83%	-0.74%	6.84%	0.15%	2.33%
EBITDA	1,030	1,049	1,026	952.48	840.2	842.97
EBITDA Margin	12.23%	12.40%	12.67%	12.70%	12.81%	14.04%
D&A For EBITDA	545.03	538.84	514.09	486.61	436.53	384.2
EBIT	485.35	510.63	512.15	465.87	403.67	458.77
EBIT Margin	5.76%	6.03%	6.32%	6.21%	6.15%	7.64%
Effective Tax Rate	9.95%	8.80%	4.99%	9.68%	14.04%	15.68%
Revenue as Reported	-	-	-	7,503	-	6,006
Advertising Expenses	-	7.46	8.95	8.18	11.33	12.84

Updated Oct 29, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.